CA
EW icon

CastleArk Alternatives’s Edwards Lifesciences EW Stock Holding History

CastleArk Alternatives’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-387,335
Closed -$43.9M – 105
2021
Q3 		$43.9M Buy
+387,335
New +$44.2M 1.68% 13

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CastleArk Alternatives's EW Position: Q4 2021 in Review

CastleArk Alternatives sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 387,335 shares — an estimated $43.9M sold.

CastleArk Alternatives first reported a position in EW in Q3 2021 and held it in 1 quarter. The position peaked at $43.9M in Q3 2021. 1,320 funds tracked by Wall St. Rank hold EW as of Q4 2021.

  • CastleArk Alternatives reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 387,335 Edwards Lifesciences shares in Q4 2021, an estimated $43.9M.
  • CastleArk Alternatives first reported a position in Edwards Lifesciences in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Edwards Lifesciences position peaked at $43.9M in Q3 2021.
  • 1,320 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.